Prognostic markers and their discriminant score in predicting the outcome of Babesia gibsoni infection

2021 ◽  
Author(s):  
Rajamanickam Kandasamy ◽  
Leela Venkatasubramanian ◽  
Karuppusamy Loganathasamy ◽  
Bhaskaran Ravi Latha ◽  
Balagangatharathilagar Mani
Keyword(s):  
Prognostic Markers ◽  
Babesia Gibsoni ◽  
Discriminant Score

372: Identification of Molecular Subtypes and Prognostic Markers in Renal Cell Carcinomas Using CDNA Microarray

2005 ◽  
Vol 173 (4S) ◽  
pp. 102-102 ◽  
Author(s):  
Hongjuan Zhao ◽  
Eric Bair ◽  
Robert Tibshirani ◽  
Börje Ljungberg ◽  
James D. Brooks
Keyword(s):  
Cdna Microarray ◽  
Renal Cell ◽  
Prognostic Markers ◽  
Molecular Subtypes ◽  
Renal Cell Carcinomas

743: Methylation of the E-Cadherin and the TIMP-3 Genes are Positive Prognostic Markers for Patients with Non-Muscle Invasive Bladder Carcinoma

2004 ◽  
Vol 171 (4S) ◽  
pp. 197-197
Author(s):  
Martin G. Friedrich ◽  
Gangning Liang ◽  
Marieta I. Toma ◽  
Daniel J. Weisenberger ◽  
Jonathan C. Cheng ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Prognostic Markers ◽  
Muscle Invasive ◽  
E Cadherin

Evaluation of kallikrein-related peptidase 5 [KLK5] and Survivin as Prognostic Markers in Breast Cancer

2012 ◽  
Vol 3 (5) ◽  
pp. 398-401
Author(s):  
Maha Imam Ahmed Ismail ◽  
◽  
* Manal Basyouni Ahmed * Manal Basyouni Ahmed ◽  
Muneera Al-Sheeha
Keyword(s):  
Breast Cancer ◽  
Prognostic Markers

FETAL GROWTH RESTRICTION WITH EARLY AND LATE MANIFESTATION, PROGNOSTIC MARKERS

2020 ◽  
pp. 27-30
Author(s):  
Yakubova D.I.
Keyword(s):  
Risk Factors ◽  
Pregnant Women ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Prenatal Screening ◽  
Prognostic Markers ◽  
Growth Restriction ◽  
Late Manifestation ◽  
Late Form ◽  
Early Manifestation

Objective of the study: Comprehensive assessment of risk factors, the implementation of which leads to FGR with early and late manifestation. To evaluate the results of the first prenatal screening: PAPP-A, B-hCG, made at 11-13 weeks. Materials and Methods: A retrospective study included 110 pregnant women. There were 48 pregnant women with early manifestation of fetal growth restriction, 62 pregnant women with late manifestation among them. Results of the study: The risk factors for the formation of the FGR are established. Statistically significant differences in the indicators between groups were not established in the analyses of structures of extragenital pathology. According to I prenatal screening, there were no statistical differences in levels (PAPP-A, b-hCG) in the early and late form of FGR.

Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review

2020 ◽  
Vol 27 (12) ◽  
pp. 1276-1287
Author(s):  
Brigida Anna Maiorano ◽  
Giovanni Schinzari ◽  
Sabrina Chiloiro ◽  
Felicia Visconti ◽  
Domenico Milardi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Neuroendocrine Tumors ◽  
Prognostic Markers ◽  
State Of The Art ◽  
Therapeutic Targets ◽  
The State ◽  
Pancreatic Neuroendocrine Tumors ◽  
Rare Tumors ◽  
Personalized Approach ◽  
Future Management

Pancreatic neuroendocrine tumors (PanNETs) are rare tumors having usually an indolent behavior, but sometimes with unpredictable aggressiveness. PanNETs are more often non-functioning (NF), unable to produce functioning hormones, while 10-30% present as functioning (F) - PanNETs, such as insulinomas , gastrinomas , and other rare tumors. Diagnostic and prognostic markers, but also new therapeutic targets, are still lacking. Proteomics techniques represent therefore promising approaches for the future management of PanNETs. We conducted a systematic review to summarize the state of the art of proteomics in PanNETs. A total of 9 studies were included, focusing both on NF- and F-PanNETs. Indeed, proteomics is useful for the diagnosis, the prognosis and the detection of therapeutic targets. However, further studies are required. It is also warranted to standardize the analysis methods and the collection techniques, in order to validate proteins with a relevance in the personalized approach to PanNETs management.

Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma

2020 ◽  
Vol 20 (11) ◽  
pp. 875-886
Author(s):  
Yingyi Wang ◽  
Bao Jin ◽  
Na Zhou ◽  
Zhao Sun ◽  
Jiayi Li ◽  
...  
Keyword(s):  
Antitumor Immunity ◽  
Prognostic Markers ◽  
Immune Cell ◽  
Neutrophil Infiltration ◽  
Computational Biophysics ◽  
Extrahepatic Cholangiocarcinoma ◽  
Whole Exome ◽  
Mutation Burden ◽  
Long Term Survivors

Background:: Neoantigens are newly formed antigens that have not been previously recognized by the immune system. They may arise from altered tumor proteins that form as a result of mutations. Although neoantigens have recently been linked to antitumor immunity in long-term survivors of cancers, such as melanoma and colorectal cancer, their prognostic and immune-modulatory role in many cancer types remains undefined. Objective: The purpose of this study is to identify prognostic markers for long-term extrahepatic cholangiocarcinoma (EHCC) survival. Methods: We investigated neoantigens in EHCC, a rare, aggressive cancer with a 5-year overall survival rate lower than 10%, using a combination of whole-exome sequencing (WES), RNA sequencing (RNA-seq), computational biophysics, and immunohistochemistry. Results: : Our analysis revealed a decreased neutrophil infiltration-related trend of high-quality neoantigen load with IC50 <500 nM (r=-0.445, P=0.043). Among 24 EHCC patients examined, we identified four long-term survivors with WDFY3 neoantigens and none with WDFY3 neoantigens in the short-term survivors. The WDFY3 neoantigens are associated with a lower infiltration of neutrophils (p=0.013), lower expression of CCL5 (p=0.025), CXCL9 (p=0.036) and TIGIT (p=0.016), and less favorable prognosis (p=0.030). In contrast, the prognosis was not significantly associated with tumor mutation burden, neoantigen load, or immune cell infiltration. Conclusion:: We suggest that the WDFY3 neoantigens may affect prognosis by regulating antitumor immunity and that the WDFY3 neoantigens may be harnessed as potential targets for immunotherapy of EHCC.

Sign in / Sign up

Export Citation Format

Share Document